Genetron Holdings Limited (“Genetron Health” or the “Company”)
(Nasdaq: GTH), a leading precision oncology company in China that
specializes in offering molecular profiling tests, and dMed
Biopharmaceutical (“dMed”), a next generation full service Clinical
Contract Research Organization (CRO) in China, today announced that
the two companies have signed a partnership agreement that pioneers
a "one-stop" new drug research and development (R&D) service
offering and registration services in both China and the U.S. for
biopharmaceutical companies.
Under the agreement, the two sides will join forces in the field
of oncology. Genetron Health will provide its innovative technology
and expertise in precision oncology, covering central laboratory
services, new drug development and target screening, companion
diagnostic development, clinical trial patient screening and
enrollment. Meanwhile, dMed will devote its efforts to new drug
R&D design, clinical operations, data management and
statistical analysis, project management and regulatory
affairs.
As a leading precision oncology company in China, Genetron
Health has partnered with dozens of global and domestic
pharmaceutical companies, providing standard “one-stop” R&D and
registration services through its global molecular profiling
platform. The Company also has five laboratories in China, which
have passed external quality assessment by China’s National Center
for Clinical Laboratories (NCCL) with full grades for five
consecutive years. In addition, the Beijing lab is one of the few
domestic labs that are both CAP and CLIA certified, while the CLIA
lab in Maryland, U.S. is under construction to serve global
pharmaceutical companies on R&D and commercialization.
Currently, Genetron Health has received seven IVD product
approvals, with seven others in the pipeline. These products and
product candidates cover three major technology platforms: NGS,
dPCR and qPCR. The NGS platform provides flexible combinations of
targeted panel products and comprehensive genomic profiling
product.
Since its launch four years ago, dMed has delivered high-quality
clinical trial services for over 400 innovative Chinese and global
biopharma companies, demonstrating the benefits of a
next-generation CRO with global capacity and standards. dMed has
recruited talents in both China and the U.S. and employs around 600
professionals globally. dMed has offices in major global cities,
including Shanghai, Beijing, Wuhan, New York, Washington, San
Francisco, and Brussels. In 2019, dMed completed the acquisition of
Target Health, a full-service New York-based CRO, to further extend
its global footprint and service offerings.
“We are impressed by dMed’s strengths in early R&D design,
clinical capabilities and data analysis. Based on our proprietary
technologies such as the One-Step Seq method and our experience in
precision oncology, we have further enhanced our molecular
diagnostic technology platforms and service systems to achieve
higher efficiency. Joining forces with strategic partners such as
dMed, Genetron Health’s capability will be further utilized to
provide more comprehensive and flexible R&D solutions for
domestic and global companies in oncology drug development,” said
Sizhen Wang, co-founder and CEO of Genetron Health.
Dr. Lingshi Tan, founder and CEO of dMed, said: “Genetron Health
is a leading precision oncology company in China and we are very
excited about our collaboration. dMed has a strong team that is
deeply experienced in the clinical development of oncology drugs,
of which a quarter of our employees have more than ten years of
work experience in top MNC pharmaceutical or leading CRO companies.
Our company also strives for excellent customer service. I firmly
believe that the strategic partnership with Genetron Health will
allow us to leverage both parties’ strengths, and together we can
help our customers increase their clinical R&D efficiencies,
shorten their research cycles, boost their success rates, and
ultimately benefit patients.”
About Genetron Holdings Limited
Genetron Holdings Limited (“Genetron Health” or the “Company”)
(Nasdaq: GTH) is a leading precision oncology platform company in
China that specializes in cancer molecular profiling and harnesses
advanced technologies in molecular biology and data science to
transform cancer treatment. The Company has developed a
comprehensive oncology portfolio that covers the entire spectrum of
cancer management, addressing needs and challenges from early
screening, diagnosis and treatment recommendations, as well as
continuous disease monitoring and care. Genetron Health also
partners with global biopharmaceutical companies and offers
customized services and products. For more information, please
visit ir.genetronhealth.com.
About dMed Biopharmaceutical
dMed is a full-service Clinical Contract Research Organization
(CRO), which provides industry solutions to pharmaceutical and
medical device companies in China and across the globe. dMed is led
by experts in China and the US who are originated from leading
multinational pharma companies and regulatory agencies. The company
is uniquely positioned to leverage and integrate China’s new
regulatory framework, offer innovative drug development strategies,
and help their clients expand globally by tapping into the world’s
second largest pharmaceutical market. dMed’s creative and flexible
collaboration models will help Chinese and global innovative pharma
companies raise efficiency in clinical R&D, scientifically
shorten research cycle, and boost success rate.
Safe Harbor StatementThis press release contains forward-looking
statements within the meaning of federal securities laws, including
statements regarding the potential benefits and collaborations
under the partnership with dMed. These statements are made under
the “safe harbor” provisions of the U.S. Private Securities
Litigation Reform Act of 1995. Statements that are not historical
facts, including statements about the Company’s beliefs and
expectations, are forward-looking statements. Forward-looking
statements involve inherent risks and uncertainties, and a number
of factors could cause actual results to differ materially from
those contained in any forward-looking statement. In some cases,
forward-looking statements can be identified by words or phrases
such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,”
“estimate,” “intend,” “plan,” “believe,” “potential,” “continue,”
“is/are likely to” or other similar expressions. Further
information regarding these and other risks, uncertainties or
factors is included in the Company’s filings with the SEC. All
information provided in this press release is as of the date of
this press release, and the Company does not undertake any duty to
update such information, except as required under applicable
law.
Investor Relations ContactUS:Hoki LukHead of
Investor RelationsEmail: hoki.luk@genetronhealth.comPhone: +1 (408)
891-9255
Stephanie CarringtonWestwicke, an ICR CompanyEmail:
Stephanie.Carrington@westwicke.comOffice: +1 (646) 277-1282
Asia:Bill ZimaICR, Inc.Email:
bill.zima@icrinc.comir@genetronhealth.com
Media Relations ContactEdmond
LococoICREdmond.Lococo@icrinc.comMobile: +86
138-1079-1408pr@genetronhealth.com
Genetron (NASDAQ:GTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Genetron (NASDAQ:GTH)
Historical Stock Chart
From Jul 2023 to Jul 2024